Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. / Jensen, Gorm B; Hilden, Jørgen; Als-Nielsen, Bodil; Damgaard, Morten; Hansen, Jørgen Fischer; Hansen, Stig; Helø, Olav H; Hildebrandt, Per; Kastrup, Jens; Kolmos, Hans Jørn; Kjøller, Erik; Lind, Inga; Nielsen, Henrik; Petersen, Lars; Jespersen, Christian M; Gluud, Christian; CLARICOR Trial Group; Jensen, Gorm B; Hilden, Jørgen; Als-Nielsen, Bodil; Damgaard, Morten; Hansen, Jørgen Fischer; Hansen, Stig; Helø, Olav Holger; Hildebrandt, Per; Kastrup, Jens; Kolmos, Hans Jørn; Kjøller, Erik; Lind, Inga; Nielsen, Henrik; Petersen, Lars; Jespersen, Christian; Gluud, Christian; CLARICOR Trial Group.

In: Journal of Cardiovascular Pharmacology, Vol. 55, No. 2, 01.02.2010, p. 123-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jensen, GB, Hilden, J, Als-Nielsen, B, Damgaard, M, Hansen, JF, Hansen, S, Helø, OH, Hildebrandt, P, Kastrup, J, Kolmos, HJ, Kjøller, E, Lind, I, Nielsen, H, Petersen, L, Jespersen, CM, Gluud, C, CLARICOR Trial Group, Jensen, GB, Hilden, J, Als-Nielsen, B, Damgaard, M, Hansen, JF, Hansen, S, Helø, OH, Hildebrandt, P, Kastrup, J, Kolmos, HJ, Kjøller, E, Lind, I, Nielsen, H, Petersen, L, Jespersen, C, Gluud, C & CLARICOR Trial Group 2010, 'Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease', Journal of Cardiovascular Pharmacology, vol. 55, no. 2, pp. 123-8. https://doi.org/10.1097/FJC.0b013e3181c87e37, https://doi.org/10.1097/FJC.0b013e3181c87e37

APA

Jensen, G. B., Hilden, J., Als-Nielsen, B., Damgaard, M., Hansen, J. F., Hansen, S., Helø, O. H., Hildebrandt, P., Kastrup, J., Kolmos, H. J., Kjøller, E., Lind, I., Nielsen, H., Petersen, L., Jespersen, C. M., Gluud, C., CLARICOR Trial Group, Jensen, G. B., Hilden, J., ... CLARICOR Trial Group (2010). Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology, 55(2), 123-8. https://doi.org/10.1097/FJC.0b013e3181c87e37, https://doi.org/10.1097/FJC.0b013e3181c87e37

Vancouver

Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology. 2010 Feb 1;55(2):123-8. https://doi.org/10.1097/FJC.0b013e3181c87e37, https://doi.org/10.1097/FJC.0b013e3181c87e37

Author

Jensen, Gorm B ; Hilden, Jørgen ; Als-Nielsen, Bodil ; Damgaard, Morten ; Hansen, Jørgen Fischer ; Hansen, Stig ; Helø, Olav H ; Hildebrandt, Per ; Kastrup, Jens ; Kolmos, Hans Jørn ; Kjøller, Erik ; Lind, Inga ; Nielsen, Henrik ; Petersen, Lars ; Jespersen, Christian M ; Gluud, Christian ; CLARICOR Trial Group ; Jensen, Gorm B ; Hilden, Jørgen ; Als-Nielsen, Bodil ; Damgaard, Morten ; Hansen, Jørgen Fischer ; Hansen, Stig ; Helø, Olav Holger ; Hildebrandt, Per ; Kastrup, Jens ; Kolmos, Hans Jørn ; Kjøller, Erik ; Lind, Inga ; Nielsen, Henrik ; Petersen, Lars ; Jespersen, Christian ; Gluud, Christian ; CLARICOR Trial Group. / Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. In: Journal of Cardiovascular Pharmacology. 2010 ; Vol. 55, No. 2. pp. 123-8.

Bibtex

@article{df734720829b11df928f000ea68e967b,
title = "Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease",
abstract = "In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.",
author = "Jensen, {Gorm B} and J{\o}rgen Hilden and Bodil Als-Nielsen and Morten Damgaard and Hansen, {J{\o}rgen Fischer} and Stig Hansen and Hel{\o}, {Olav H} and Per Hildebrandt and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Erik Kj{\o}ller and Inga Lind and Henrik Nielsen and Lars Petersen and Jespersen, {Christian M} and Christian Gluud and {CLARICOR Trial Group} and Jensen, {Gorm B} and J{\o}rgen Hilden and Bodil Als-Nielsen and Morten Damgaard and Hansen, {J{\o}rgen Fischer} and Stig Hansen and Hel{\o}, {Olav Holger} and Per Hildebrandt and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Erik Kj{\o}ller and Inga Lind and Henrik Nielsen and Lars Petersen and Christian Jespersen and Christian Gluud and Nielsen, {Henrik Anker}",
year = "2010",
month = feb,
day = "1",
doi = "10.1097/FJC.0b013e3181c87e37",
language = "English",
volume = "55",
pages = "123--8",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

AU - Jensen, Gorm B

AU - Hilden, Jørgen

AU - Als-Nielsen, Bodil

AU - Damgaard, Morten

AU - Hansen, Jørgen Fischer

AU - Hansen, Stig

AU - Helø, Olav H

AU - Hildebrandt, Per

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Kjøller, Erik

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Petersen, Lars

AU - Jespersen, Christian M

AU - Gluud, Christian

AU - CLARICOR Trial Group

AU - Jensen, Gorm B

AU - Hilden, Jørgen

AU - Als-Nielsen, Bodil

AU - Damgaard, Morten

AU - Hansen, Jørgen Fischer

AU - Hansen, Stig

AU - Helø, Olav Holger

AU - Hildebrandt, Per

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Kjøller, Erik

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Petersen, Lars

AU - Jespersen, Christian

AU - Gluud, Christian

AU - CLARICOR Trial Group

PY - 2010/2/1

Y1 - 2010/2/1

N2 - In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.

AB - In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.

U2 - 10.1097/FJC.0b013e3181c87e37

DO - 10.1097/FJC.0b013e3181c87e37

M3 - Journal article

C2 - 19920766

VL - 55

SP - 123

EP - 128

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -

ID: 20544589